Immune cell therapy aims to stop bladder bleeding in transplant patients
NCT ID NCT07638332
First seen Jun 22, 2026 · Last updated Jun 22, 2026
Summary
This early-stage trial tests a treatment called LB-DTK-BKV, which uses specially trained immune cells from a donor to fight BK virus. The virus can cause painful bladder bleeding in people who have had a stem cell transplant. About 42 children and adults will receive two infusions of these cells. Researchers will check if the treatment lowers virus levels and is safe, comparing it to standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMORRHAGIC CYSTITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center
Seoul, Seoul, 05505, South Korea
Contact
-
Chonnam National University Hwasun Hospital
Hwasun, 58128, South Korea
Contact
-
Ewha Womans University Seoul Hospital
Seoul, 07804, South Korea
Contact
-
Kyungpook National University Chilgok Hospital
Daegu, 41404, South Korea
Contact
-
National Cancer Center Korea
Goyang-si, 10408, South Korea
Contact
-
Samsung Seoul Hospital
Seoul, Seoul, 06351, South Korea
Contact
-
Seoul National University Hospital
Seoul, Seoul, 03080, South Korea
Contact
-
Severance Hospital
Seoul, Seoul, 03722, South Korea
-
Ulsan University Hospital
Ulsan, 44033, South Korea
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LB-DTK-BKV (immune cells trained to fight BK virus)
What this could lead to
If it works, this could offer a new treatment for painful bladder bleeding caused by BK virus in transplant patients, potentially reducing virus levels and symptoms.
What could go wrong
This is an early phase 1/2 trial with only 42 participants, so results may not apply to everyone. The treatment involves donor immune cells, which could cause side effects like infusion reactions or graft-versus-host disease.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.